Latest stories on NTLA
Intellia Therapeutics (NTLA) Secured a Facility for Up to $400M. Is It Worth the Cost?
Yahoo Top38 · neutralgeneral
Cathie Wood’s ARK Investment buys 204K shares of Intellia Therapeutics today
The Fly63 · neutralgeneral
Intellia Therapeutics price target raised to $13 from $12 at Wedbush
The Fly61 · neutralanalyst
H.C. Wainwright reiterates Intellia stock rating on FDA review progress
Investing.com Analyst Ratings56 · neutralanalyst
Citizens reiterates Intellia stock rating on FDA priority review
Investing.com Analyst Ratings56 · neutralanalyst
Intellia Therapeutics, Inc. (NTLA) files 8-K
SEC 8-K50 · neutralgeneral
Cathie Wood’s Biotech Bet Intellia Secured An FDA Priority Review For Rare Genetic Disorder Therapy – Retail Sees Upside In NTLA’s Platform
Stocktwits News67 · bullishproduct/pr
Why is Intellia Therapeutics stock rallying today?
Investing.com Markets50 · neutralgeneral
Intellia rises on FDA priority review for one-time hereditary angioedema therapy
Seeking Alpha67 · bullishproduct/pr
Intellia Therapeutics Shares Rise as FDA Grants Priority Review to Lonvo-z
InvestorsHub67 · bullishproduct/pr
Intellia Therapeutics stock jumps on FDA priority review
Investing.com Markets67 · bullishproduct/pr
Intellia Therapeutics announces FDA acceptance of lonvo-z BLA
The Fly63 · neutralgeneral
Citizens reiterates Intellia stock rating on HAE opportunity potential
Investing.com Analyst Ratings56 · neutralanalyst
Intellia Therapeutics Secures Major Non-Dilutive Loan Financing
TipRanks68 · bullishgeneral
Intellia Therapeutics, Inc. (NTLA) files 8-K
SEC 8-K50 · neutralgeneral
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
StockTitan50 · neutralgeneral
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Insider50 · neutralgeneral
Intellia Therapeutics secures $400M loan facility
Seeking Alpha46 · neutralgeneral
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
GlobeNewswire59 · neutralgeneral
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
Business Insider59 · neutralgeneral
Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
GlobeNewswire55 · neutralgeneral
Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
StockTitan56 · neutralgeneral